Zanidatamab+ chemotherapy ±tislelizumab for first-line HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma: Primary analysis from HERIZON-GEA-01

ASCO GI 2026 • Gastric Cancer • Tislelizumab • Oral

Elimova E

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

VIEW PRESENTATION DOWNLOAD PDF

Related Content

CONGRESS

Evaluation of PET-CT metrics and pharmacokinetics in adults receiving tislelizumab for relapsed/refractory classical Hodgkin lymphoma: Ancillary analyses of LYSA Phase 2 TIRHOL study BGB-A317-210

EHA 2026 • Hodgkin lymphoma • Tislelizumab • Poster

Hervé Ghesquières, MD, PhD

FIND OUT MORE
CONGRESS

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53

EHA 2026 • CLL/SLL • Sonrotoclax, Zanubrutinib • Oral

Chan Y. Cheah, MBBS, DMSc

FIND OUT MORE
CONGRESS

BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A Phase 1 CaDAnCe-101 study update

EHA 2026 • CLL/SLL • BGB-16673 • Oral

Stephan Stilgenbauer, MD

FIND OUT MORE

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed